Lindsay A. Rosenwald, M.D. – Executive Chairman of the Board of Directors

Dr. Rosenwald has almost 25 years of experience as a biotechnology entrepreneur, including the founding and recapitalization of numerous public and private biotechnology and life sciences companies. In addition to serving as Cyprium’s Executive Chairman, Dr. Rosenwald is Chairman and CEO of Fortress Biotech, Cyprium’s parent company, and a member of Fortress’ Board of Directors. Dr. Rosenwald is also a Co-Portfolio Manager and Partner at Opus Point Partners Management, LLC, a life-science focused asset management firm that is affiliated with Fortress. Before moving into his current positions, Dr. Rosenwald served as Chairman of Paramount BioCapital, Inc. Dr. Rosenwald received an M.D. from Temple University School of Medicine and a B.S. in finance from Pennsylvania State University.

Lung S. Yam, M.D., Ph.D., Chief Executive Officer and Director

Lung S. Yam, M.D., Ph.D., Chief Executive Officer of Cyprium, co-founded Cyprium as part of his Business Development Consultant role at Fortress, where he identified multiple opportunities across diverse therapeutic areas leading to the in-licensing of multiple assets, including CUTX-101 and the AAV-ATP7A gene therapy program. In addition to his roles at Cyprium and Fortress, Dr. Yam serves as Senior Advisor at Opus Point Partners, LLC, an affiliated life-science focused asset management firm. Prior to joining Opus Point Partners, Dr. Yam was an equity research associate at Rodman & Renshaw, LLC. Dr. Yam earned M.D. and Ph.D. degrees from New York University School of Medicine, and a B.A. in biology from Johns Hopkins University, where he graduated Phi Beta Kappa.

Michael Weiss – Director

Mr. Weiss is a member of Cyprium’s Board of Directors and Executive Vice Chairman, Strategic Development, of Cyprium’s parent company, Fortress Biotech, where he also serves as Co-Vice Chairman of its Board of Directors. In addition to his roles at Fortress, Mr. Weiss is Executive Chairman, President and CEO of TG Therapeutics, Inc. (NASDAQ: TGTX), a publicly traded biotechnology company that he co-founded in 2011 to focus on the acquisition, development and commercialization of drugs for the treatment of B-cell malignancies, and is Co-Portfolio Manager and Partner at Opus Point Partners Management, LLC. Previously, Mr. Weiss was Chairman and CEO of Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), where he led efforts to acquire and develop its lead drug Zerenex, and executed a strategic alliance for Zerenex with JT Tobacco, Inc., and Torii Pharmaceutical Co., Ltd., totaling more than $100 million. Mr. Weiss began his career as a lawyer at Cravath, Swaine & Moore LLP in New York City. He earned a J.D. from Columbia University Law School and a B.S. in finance from The State University of New York at Albany.

Cyprium was founded by Dr. Rosenwald, Dr. Yam and Mr. Weiss in 2017.